A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Debbie G J RobbrechtJuanita LopezEmiliano CalvoXiaomin HeHirai HiroshiNital SoniNatalie CookAfshin DowlatiAngelica FasoloVictor MorenoFerry A L M EskensJohann S de BonoPublished in: British journal of cancer (2020)
NCT02448589.